Skip to main content

Jentadueto FDA Approval History

FDA Approved: Yes (First approved January 30, 2012)
Brand name: Jentadueto
Generic name: linagliptin and metformin hydrochloride
Dosage form: Tablets
Company: Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly
Treatment for: Diabetes, Type 2

Jentadueto (linagliptin and metformin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Development timeline for Jentadueto

DateArticle
May 31, 2016Approval FDA Approves Once-Daily Jentadueto XR (linagliptin and metformin hydrochloride extended-release) for Type 2 Diabetes
Feb  1, 2012Approval FDA Approves Jentadueto (linagliptin/metformin hydrochloride) for the Treatment of Adult Patients with Type 2 Diabetes

See also

Jentadueto (linagliptin and metformin hydrochloride) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer